Treatment options available for patients with AL amyloidosis beyond chemotherapy & transplant

Efstathios Kastritis, MD, University of Athens, Athens, Greece, proposes treatment strategies for patients with light chain (AL) amyloidosis beyond stem cell transplantation (SCT) and chemotherapy, commenting on the role of venetoclax, lenalidomide- and pomalidomide-containing regimens, and other novel agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.